Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Rugo, Hope S.; Herbst, Roy S.; Liu, Glenn; Park, John W.; Kies, Merrill S.; Steinfeldt, Heidi; Pithavala, Yazdi K.; Reich, Steven D.; Freddo, James L.; Wilding, George

doi:10.1200/jco.2005.04.192

Cited by 453 publications

(289 citation statements)

References 36 publications

(5 reference statements)

Supporting

Mentioning

277

Contrasting

Unclassified

Order By: Relevance

“…[46] Hypertension and stomatitis were the main dose-limiting toxicities seen during the phase I study; these were mainly observed with higher doses of axitinib. Other adverse events (AEs) included fatigue, diarrhea, nausea, and vomiting.…”

Section: Axitinib Antitumor Activitymentioning

confidence: 99%

See 1 more Smart Citation

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Escudier

Gore

2011

Drugs R D

View full text Add to dashboard Cite

Section: Axitinib Antitumor Activitymentioning

confidence: 99%

“…Other adverse events (AEs) included fatigue, diarrhea, nausea, and vomiting. [46] 3. Pharmacokinetics/Pharmacodynamics…”

Section: Axitinib Antitumor Activitymentioning

confidence: 99%

Axitinib for the Management of Metastatic Renal Cell Carcinoma

Escudier

Gore

2011

Drugs R D

View full text Add to dashboard Cite

“…The median time to progression was 7.2 months and median overall survival was 18.7 months. A trial testing another multikinase and VEGFR inhibitor, axitinib, is currently underway (Table 2); 1 patient treated with this agent reportedly achieved a partial response that lasted 4 months 76…”

Section: Introductionmentioning

confidence: 99%

Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials

Chakraborty²,

et al. 2015

View full text Add to dashboard Cite

BackgroundAdenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed.MethodsA search of articles in PubMed and of abstracts from national meetings was performed regarding ACC.ResultsRecent genetic analyses found that recurrent chromosome 6:9 translocations in ACC generate an MYB:NFIB gene fusion resulting in overexpression of the MYB oncoprotein. Several other frequent mutations are recently published that may be relevant for drug development. Several trials of targeted drugs are reviewed. Some agents delay tumor progression, but tumor responses remain rare.ConclusionACCs have a characteristic chromosomal translocation, but also frequently pick up additional mutations. Clinical research is limited by the rarity and slow growth of ACC. Several ongoing trials are testing agents that inhibit fibroblast growth factor receptor signaling or other signaling pathways. Novel treatments based on the recently sequenced tumor genome are under development. © 2015 The Authors Head & Neck Published by Wiley Periodicals, Inc. 38: 620–627, 2016

show abstract

“…Drug response was studied across a range of doses based on published data from phase I trials reporting a C max of 72ng/ml and 63ng/ml for sunitinib and axitinib with recommended treatment doses (50mg daily and 5mg twice daily respectively) [169,170]. Minimal responses were seen at 120 …”

Section: Cell Viability Studies In the Presence Of Tkimentioning

confidence: 99%